IL10 and myeloid sarcoma: Over time, numerous innovative modifying therapies have been developed for MS treatment that mainly focused on the modulation of the immune system through the decrease in Th1 and Th17 activation, induction of Th2 and Treg differentiation, and immunomodulatory cytokines production, such as IL-10 and TGF-β, reduction in BBB permeability, and suppression lymphocyte migration to the CNS [10,11].